相互作用
Aprepitant + Entrectinib
重症度: 重大
Aprepitant and Entrectinib: major interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Aprepitant can raise entrectinib exposure through CYP3A4 inhibition. This increases risks such as QT prolongation, heart failure, CNS effects and hepatic toxicity.
この相互作用をわかりやすく説明すると
Aprepitant and Entrectinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Aprepitant belongs to Gastrointestinal Tract; Entrectinib belongs to Oncology.
なぜ起こるのか
Aprepitant inhibits CYP3A4, the primary enzyme metabolizing entrectinib.
対処法
Avoid the combination where possible. If unavoidable, reduce entrectinib to 200 mg daily in adults and eligible adolescents, monitor QTc, and restore the dose 3 to 5 half-lives after stopping aprepitant.
薬剤師に尋ねること
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、AprepitantとEntrectinibの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を14日間無料でお試し。カード登録不要。
Aprepitantのその他の相互作用
Entrectinibのその他の相互作用
よくある質問
Can I take Aprepitant with Entrectinib?
MediHelp rates the interaction as major. Aprepitant and Entrectinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Aprepitant can raise entrectinib exposure through CYP3A4 inhibition. This increases risks such as QT prolongation, heart failure, CNS effects and hepatic toxicity.
How serious is the interaction between Aprepitant and Entrectinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination where possible. If unavoidable, reduce entrectinib to 200 mg daily in adults and eligible adolescents, monitor QTc, and restore the dose 3 to 5 half-lives after stopping aprepitant.
What other medicines interact with Aprepitant?
MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
